Latigo Biotherapeutics secured $150 million in Series B financing led by Blue Owl Capital to accelerate the development of innovative non-opioid pain treatments.

Target Overview

Latigo Biotherapeutics is a clinical-stage biotechnology firm that specializes in the development of non-opioid pain medications, innovatively designed to address pain at its source. As of March 17, 2025, Latigo has successfully secured $150 million in Series B financing to further its clinical programs, particularly focusing on selective Na v 1.8 inhibitors.

The proceeds from this financing round will enhance Latigo’s ongoing clinical developments, including the advancement of its promising pipeline aimed at delivering safer, more effective pain management solutions. Latigo is committed to revolutionizing pain treatment, with a goal to eliminate the need for addictive substances.

Industry Overview

The demand for non-opioid pain treatments has heightened in recent years, particularly in the U.S., where opioid addiction and overdose rates have surged. The healthcare industry has recognized the urgent need for alternatives